Nevro’s HFX iQ Spinal Cord Stimulation System Receives the US FDA’s Approval for the Treatment of Chronic Pain
Shots:
- The US FDA has approved Senza HFX iQ spinal cord stimulation system to treat chronic pain. The system has been developed to optimize care by collecting patient data, maintaining long-term pain relief, improving life quality & guiding them through a personalized treatment process
- Senza HFX iQ is the first and only SCS system that uses AI & a superior high-frequency 10 kHz Therapy platform that offers multiple advantages over other SCS systems
- Senza HFX iQ features an HFX iQ Implantable Pulse Generator (IPG), the HFX trial stimulator, charger, and the HFX app. Nevro plans to launch it with algorithms for chronic back and leg pain, incl. non-surgical back pain & PDN at a limited scale in the US in 2022 and also plans to launch across the nation in 2023
Ref: PR Newswire | Image: Nevro
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
